Off-Label Use of Marketed Drugs in Clinical Trials: Investigational New Drug (IND) Considerations
Nov 8 12:00pm - Nov 8 01:00pm · CTRB 3256


  • Sheila Austin, MS, CIP, CTSI Regulatory Specialist
The FDA IND application and submission process for the use of a marketed drug in clinical research can seem overwhelming and not worth the effort. Don’t let a terrific research opportunity slip away because you are not familiar with the process.

Bring your lunch, learn about the tools the CTSI has developed to make this process as simple as possible, and find out how the CTSI Regulatory Specialist can help you!

Presented by the CTSI Regulatory Knowledge and Support Program